Research programme: autoimmune disease therapies- EVOQ Therapeutics
Latest Information Update: 31 Mar 2023
Price :
$50 *
At a glance
- Originator EVOQ Therapeutics
- Developer EVOQ Therapeutics; Gilead Sciences
- Class Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 03 Jan 2023 Gilead Sciences in-licenses NanoDisc technology from EVOQ Therapeutics to develop and commercialize immunotherapy products for Rheumatoid Arthritis and Lupus
- 03 Jan 2023 Early research in Rheumatoid arthritis in USA (unspecified route)
- 03 Jan 2023 Early research in Systemic lupus erythematosus in USA (unspecified route)